Wednesday, January 25, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Featured News

BARDA Backs Food-Grade Compound as Repellent Against Zika-Carrying Mosquitoes

by Global Biodefense Staff
May 30, 2017
Zika and Mosquito Vector Control

Image credit: CDC, adapted

The Biomedical Advanced Research and Development Authority (BARDA) has announced intentions to award a research and development contract to Evolva in support of a “Novel Toxicant and Repellent for Arthropod-borne Virus Vectors (NTRAVV)”.

CDC and Evolva have already entered into and executed a Cooperative Research and Development Agreement (CRADA) and a Commercial Licensing Agreement with the goals to achieve EPA registration of the biotoxicant Nootkatone as a killing agent and repellent against mosquitoes.

The requirement of this contract is to conduct all safety and efficacy trials required for such EPA registration.

The ongoing Zika virus epidemic is severely impacting the public health in Latin America and the Caribbean and appears to be spreading into Southeast Asia. In addition, Zika virus is an imminent threat to the southern part of the continental U.S., where the primary mosquito vectors, Aedes aegypti (the predominant vector) and Aedes albopictus, are widespread and abundant. While the virus produces a range of outcomes in infected individuals, the most dire and long lasting effects of infection are seen with fetuses exposed to the virus in early to mid-stages of a pregnancy.

New insecticides with modes of action that allow them to kill mosquitoes that are resistant to pyrethroids and other commonly used toxicant active ingredients are urgently needed to ensure effective emergency control of adult mosquitoes in the short term and improved management of insecticide resistance through toxicant rotations or mosaics in the long term.

Nootkatone, a plant-derived compound, has demonstrated a great deal of potential for use against the Aedes mosquito vectors that transmit Zika, yellow fever, dengue, and chikungunya viruses. Nootkatone appears to have a mode of action distinct from that of currently used toxicants and therefore may overcome the resistance issues hampering current emergency control efforts. Nootkatone presently is used in the flavor and fragrance industry and is considered “food grade” and therefore safe for human consumption and topical application.

Nootkatone and other compounds extracted from Alaska yellow cedar and common to citrus products are patented by scientists at the Centers for Disease Control and Prevention-Division of Vector-Borne Diseases (CDC/DVBD) for use to control arthropod vectors of disease agents.

Evolva has a patented yeast fermentation process for producing high-purity, food-grade Nootkatone. CDC is currently working with Evolva to evaluate formulated test products and Evolva holds a Commercial Licensing Agreement for the CDC/DVBD patents. However, CDC/DVBD lacks the formally certified laboratory facilities required to conduct the efficacy trials needed for EPA registration of Nootkatone as a mosquito toxicant and repellent.

This contract will overcome the hurdles internal to BARDA and its PHEMCE partners through engaging external expertise to rapidly conduct all safety and efficacy trials required for EPA registration of the biotoxicant Nootkatone as a killing agent (toxicant) and repellent against mosquitoes of public health importance.

Source: FBO.gov

Tags: ASPRAwardsBARDAEmerging ThreatsHHSMosquito-BorneZika

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC